Rocket Pharmaceuticals, Inc. cash flow to debt ratio of -763.81% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Rocket Pharmaceuticals, Inc.'s free cash flow has increased -11.66% from $-215.59M last year to $-190.45M, signaling increasing performance

Rocket Pharmaceuticals, Inc.'s debt to equity ratio is 0.10, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.

Rocket Pharmaceuticals, Inc.'s debt has increased relative to shareholder equity from 0.06 last year to 0.10 today, signaling weakened financials

Rocket Pharmaceuticals, Inc. has negative EBITDA, making leverage ratio unreliable

Rocket Pharmaceuticals, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Rocket Pharmaceuticals, Inc. has insufficient data to evaluate this check.

Rocket Pharmaceuticals, Inc.'s short-term assets of $192.73M exceed its short-term liabilities of $30.21M

Rocket Pharmaceuticals, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Rocket Pharmaceuticals, Inc.'s return on equity of -70.79%, is lower than 15.00%, indicating bad performance

Rocket Pharmaceuticals, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Rocket Pharmaceuticals, Inc. had positive net income in only 0.00 out of 5 years, indicating unstable earnings

Rocket Pharmaceuticals, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Rocket Pharmaceuticals, Inc. has negative free cash flow, indicating cash burn

Rocket Pharmaceuticals, Inc.'s yearly earnings has increased -13.77% since last year from $-258.75M to $-223.12M, signaling increasing performance

Rocket Pharmaceuticals, Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -81.81% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Rocket Pharmaceuticals, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

Rocket Pharmaceuticals, Inc. had revenue growth in 5.00 out of 5 years, indicating consistent revenue performance

Rocket Pharmaceuticals, Inc. had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity

Rocket Pharmaceuticals, Inc. has insufficient data to evaluate this check.

Rocket Pharmaceuticals, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Rocket Pharmaceuticals, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Rocket Pharmaceuticals, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Rocket Pharmaceuticals, Inc. has insufficient data to evaluate this check.

Rocket Pharmaceuticals, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Rocket Pharmaceuticals, Inc. has a price-to-book ratio of 1.53x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Rocket Pharmaceuticals, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue